XPO1 and plasma cell myeloma: The therapeutic efficacy of XPO1 inhibition in patients has led to FDA approval of selinexor for the treatment of patients with multiple myeloma and DLBCL in the USA, and conditional marketing authorization by the European Commission for patients with multiple myeloma.